Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life SettingMariele Gatto, Roberto Gerli, Micaela Fredi et al.|Arthritis & Rheumatology|2020Cited by 113
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Andrea Doria, Laura Andréoli et al.|Journal of Autoimmunity|2017Cited by 102